Tramadol/Diclofenac Fixed-dose Combination Phase III Trial in Acute Pain After Third Molar Extraction

NCT ID: NCT03714672

Last Updated: 2019-07-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 1151 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-08-26
• Study Completion Date: 2018-03-22

Brief Summary

This study evaluated a new drug fixed-dose combination tablet (FDC) called tramadol/diclofenac at two different strengths (fixed doses of 25 milligrams [mg] of tramadol and of diclofenac or of 50 mg each). Tramadol and diclofenac each relieve pain, but they do so by different mechanisms. They were used alone as comparator drug in this study. Both are marketed drugs and are standard treatment for acute pain, including wisdom tooth removal.

Detailed Description

The purpose of this study was to demonstrate that the FDC of Tramadol and Diclofenac 50/50 has superior analgesic effect than the monotherapies and that the FDC of Tramadol and Diclofenac 25/25 has non-inferior analgesic effect than the monotherapies. There was an Enrollment Period, a blinded Treatment Period, and a Follow-up Period. Previously used analgesic medication was washed out for at least 24 hours before surgery. The Treatment Period starts on Day 1 with dental surgery and treatment allocation. Treatment was started within 4 hours after the end of surgery if the participant's pain intensity had reached at least 5 points on the 11-point numerical rating scale (NRS). Each participant received 3 doses of one of the four treatments within 24 hours. One fourth of the participants received the fixed-dose combination tablet at a low dose, one fourth at the higher dose, one fourth received 50 mg of the comparator tramadol alone, and one fourth 50 mg of the comparator diclofenac alone.

The first 2 doses of the investigational medicinal product (IMP) were taken at the site, the last dose in an out-patient setting. Participants returned to the site at 24 hours after the first dose. A Follow-up Period included a final visit at the site or a phone call on Day 14 to assess the participant's safety.

Conditions

Acute Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Tramadol/Diclofenac 50/50

Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.

Group Type: EXPERIMENTAL

Tramadol/Diclofenac 50/50

Intervention Type: DRUG

Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.

Tramadol 50

Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.

Group Type: ACTIVE_COMPARATOR

Tramadol 50

Intervention Type: DRUG

Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.

Diclofenac 50

Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction

Group Type: ACTIVE_COMPARATOR

Diclofenac 50

Intervention Type: DRUG

Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.

Tramadol/Diclofenac 25/25

Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.

Group Type: EXPERIMENTAL

Tramadol/Diclofenac 25/25

Intervention Type: DRUG

Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.

Interventions

Tramadol/Diclofenac 50/50

Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.

Intervention Type: DRUG

Tramadol/Diclofenac 25/25

Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.

Intervention Type: DRUG

Tramadol 50

Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.

Intervention Type: DRUG

Diclofenac 50

Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.

Intervention Type: DRUG

Other Intervention Names

Adorlan Forte (Registered Trademark); Adorlan (Registered Trademark); Tramadol immediate-release capsule; Tradol (Registered Trademark); Voltaren (Registered Trademark) (diclofenac enteric-coated tablet)

Eligibility Criteria

Inclusion Criteria

1. The participant has read the informed consent form, has understood the relevant aspects of the clinical study, and grants his/her authorization to participate by signing the informed consent form prior to the inclusion in the clinical study and the performance of any procedure.

2. Male and female participants above 18 years up to 60 years.

3. Female participants of childbearing potential must be practicing an acceptable method of birth control and must have a negative urine pregnancy test at enrollment with confirmation at the Allocation Visit.

4. Participants are in good health, i.e., the medical record, vital signs, physical examination, and laboratory parameter assessments do not show any abnormal deviations impeding the participation in the clinical study.

5. Participants requiring extraction of 3 or more third molars with 2 mandibular impacted third molars.

6. Clinical and radiological diagnosis of impacted lower third molars.

7. Class I and Class II molars according to Pell and Gregory's classification (Gay Escoda et al. 2004).

8. Participants must be able to swallow the IMPs.

Exclusion Criteria

1. Findings in the medical record, vital signs, and/or physical examination demonstrating abnormal conditions of participant's general state of health preventing his/her participation in the clinical study according to the investigator's opinion.

2. Participant unable to speak, read, or write in Spanish language.

3. Clinical laboratory parameters exceed the pre-defined alert ranges (i.e., 1 standard deviation above or below the upper/lower limit of the normal ranges).

4. Known hypersensitivity to the IMPs, the anesthetic to be used during surgery, or to the rescue medication (ibuprofen, ketorolac).

5. Known alcohol or drug abuse in the last 6 months or any history of seizures. Alcohol abuse is defined as the consumption of more than 3 ounces (about 90 milliliters) of liquor or spirits or 18 ounces (about 530 milliliters) of beer per day, for 5 consecutive days during the 6-month period. Drug abuse is defined as the use of any recreational drug for 5 consecutive days during the 6 month period.

6. Participants who take analgesic medication for chronic pain, monoamine oxidase inhibitors, tricyclic antidepressants, neuroleptics, or other drugs that reduce the seizure threshold within 4 weeks of enrollment.

7. Pregnant or lactating women.

8. Participants who received systemic corticosteroids or opioid analgesics less than 2 weeks before surgery.

9. Participants with molars linked to the mandibular canal.

10. Participants requiring immediate dental procedures other than third and fourth molars extraction,

11. Participant received a long-acting non-steroidal anti-inflammatory drug within 24 hours or 5 times the elimination half-life of that drug prior to surgery, whatever the longer.

12. Participant received any analgesic medication other than short-acting pre-operative or intra-operative anesthetic agents within 24 hours before taking IMPs.

13. Participant received more than 300 mg of lidocaine in total.

14. Participant received any analgesic medication other than the IMPs immediately after the oral surgical procedure was completed.

15. Baseline pain intensity of the participant after oral surgical procedure remains below 5 points on the 11-point NRS.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Grünenthal, S.A.

INDUSTRY

Sponsor Role: collaborator

Grünenthal GmbH

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Grünenthal Study Director

Role: STUDY_DIRECTOR

Grünenthal GmbH

Locations

Private Clinic

Zapopan, Jalisco, Mexico

Private Clinic

Monterrey, Nuevo León, Mexico

Private Clinic

Monterrey, Nuevo León, Mexico

Private Clinic

Aguascalientes, , Mexico

Private Clinic

Chihuahua City, , Mexico

Private Clinic

León, , Mexico

Private Clinic

Puebla City, , Mexico

University

San Luis Potosí City, , Mexico

Countries

Mexico

References

Gay Escoda C, Piñera Penalva M, Velasco Vivancos V, Berini Aytés L. Cordales incluidos. Patología, clínica y tratamiento del tercer molar incluído. In: Gay Escoda C, Berini Aytés L. (eds.). Tratado de Cirugía Bucal. Tomo I. Madrid: Ergón; 2004. p. 355-85

Reference Type: BACKGROUND

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

U1111-1179-2333

Identifier Type: OTHER

Identifier Source: secondary_id

KF8001-01

Identifier Type: REGISTRY

Identifier Source: secondary_id

KF8001-01

Identifier Type: -

Identifier Source: org_study_id